AstraZeneca (Switzerland)

Patient-Reported Disease Activity, Health-Related Quality of Life, and Coping in Systemic Lupus Erythematosus: A Cross-Sectional Online Survey in Switzerland (Lupus-IMPACT)

The impact of systemic lupus erythematosus (SLE) on the quality of life is differently perceived by patients and physicians. This survey explored the patient perception of SLE burden, challenges, and strategies of coping. Adults with a self-reported physician-diagnosis of SLE, li...

Monoclonal Antibody Coformulations Reveal Three Interaction Patterns Governing Stability

Abstract Coformulated monoclonal antibodies (mAbs) offer a promising next-generation therapeutic strategy by combining multiple antibodies in a single drug product to enhance efficacy and improve patient compliance. However, ensuring the quality and stability of individual compon...

Characteristics, treatment patterns, and outcomes of patients with transthyretin amyloidosis: a large-scale, observational, retrospective study in China (OverTTuRe China)

Abstract Background Evidence remains limited on disease journey for transthyretin (ATTR) amyloidosis in China. This study aims to analyse China data from OverTTuRe, an observational, retrospective, multi-country cohort study. Methods Data were extracted from medical records (2013...

Tozorakimab to Prevent COPD Exacerbations

BACKGROUND: Many patients with chronic obstructive pulmonary disease (COPD) have exacerbations despite receiving standard-of-care inhaled maintenance therapy. Dysregulated interleukin-33 signaling is implicated in the pathogenesis of COPD. Tozorakimab is a monoclonal antibody tha...

Safety, Pharmacokinetics, and Predicted Neutralizing Activity of the SARS-CoV-2 Monoclonal Antibody Sipavibart: Results from Little DIPPER and the SUPERNOVA Substudy

The rapid evolution of SARS-CoV-2 has necessitated efforts to accelerate the clinical evaluation of neutralizing monoclonal antibodies. Little DIPPER and the SUPERNOVA substudy explored the feasibility of immunobridging efficacy from tixagevimab–cilgavimab to sipavibart using pre...

Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics

Clinical trials report no increased malignancy risk with benralizumab in severe asthma; however, trial populations are highly selective. To better define real-world safety, malignancy risk was compared among patients treated with benralizumab, other (non-benralizumab) biologics,...